小分子菌抑制剂作为抗癌剂:发现,分类,作用机制和临床试验
Yazmin Salinas1, Subhash C Chauhan2,3, Debasish Bandyopadhyay1,4
1School of Integrative Biological and Chemical Sciences, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA.
International journal of molecular sciences
|April 17, 2025
概括
小分子线性抑制剂通过破坏微管蛋白或激酶来向癌细胞复制. 本综述根据机制对这些药物进行了分类,探讨了改善癌症治疗的临床试验和抗体-药物联合体.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 癌症仍然是一个重大的全球健康问题,每年造成数百万人的死亡.
- 小分子线性抑制剂是抗癌药物的关键类别.
- 这些药物阻碍癌细胞分裂 (线粒分裂),阻碍增殖和促进细胞死亡.
研究的目的:
- 审查和分类小分子线性抑制剂.
- 探索它们的发现,化学和作用机制.
- 讨论它们的抗癌活性,临床试验和未来前景,包括抗体-药物联合体.
主要方法:
- 小分子线性抑制剂的文献综述和分类.
- 对向微管相关蛋白质,检查点激酶1和线粒激酶的机制的分析.
- 检查临床试验数据和抗体-药物联合策略.
主要成果:
- 小分子线性抑制剂通过各种机制表现出多样化的抗癌活性.
- 临床试验正在积极调查这些药物,其中一些药物显示出有前途.
- 抗体 - 药物联体提供了针对性传递和降低毒性的潜在策略.
结论:
- 小分子线性抑制剂代表了瘤学的重要治疗策略.
- 持续的研究和临床调查对于优化它们的使用至关重要.
- 像抗体-药物合物这样的新型输送系统可能会提高疗效并最大限度地减少副作用.
相关概念视频
Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...


